Sign In
Buy AVRO
$1.40
+0 (+0%)
At Close: Sep 19, 2024
AVROBIO Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 04'th Jun 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
4 Biotech Stocks Set to Outpace Q1 Earnings Estimates
12:10pm, Thursday, 13'th May 2021
Let us take a look at some drug/biotech stocks that are poised to beat on first-quarter earnings.
Los Angeles, California--(Newsfile Corp. - May 12, 2021) - The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROB
Is a Surprise Coming for AVROBIO (AVRO) This Earnings Season?
09:46am, Wednesday, 12'th May 2021
AVROBIO (AVRO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
LOS ANGELES, May 6, 2021 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of AVROBIO, Inc. ("AVROBI
LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.
AVROBIO: Fabrazyme's Full Approval Changes Things
08:00am, Wednesday, 05'th May 2021
AVROBIO: Fabrazyme's Full Approval Changes Things
LOS ANGELES--(BUSINESS WIRE)---- $AVRO #AVRO--INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against AVROBIO, Inc.
BREAKING ALERT: Rosen Law Firm Encourages AVROBIO, Inc. Investors with Losses to Inquire About Class Action Investigation – AVRO
11:06am, Tuesday, 04'th May 2021
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) r
Avrobio Plans Registration Trial With Kidney Biopsy Endpoint To Support Potential Full Approval Of Fabry Disease Gene Therapy
09:42am, Monday, 03'rd May 2021
Avrobio Inc (NASDAQ: AVRO) has provided an update on its regulatory plans for AVR-RD-01, its lentiviral gene therapy for Fabry disease, currently in FAB-GT Phase 2 trial. In March, the FDA granted
AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease
07:00am, Monday, 03'rd May 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today provide
Rocket Pharmaceuticals Primed for Takeoff
06:19pm, Monday, 15'th Mar 2021
With all due respect to Elton John, the real Rocket Man is in Cranbury, New Jersey.
AVROBIO Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
07:00am, Friday, 05'th Mar 2021
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AVRO--AVROBIO, Inc. (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announc
Avrobio's Cystinosis Gene Therapy Gets Orphan Drug Status In Europe
11:56am, Monday, 01'st Mar 2021
The European Commission has designated Orphan Drug status to Avrobio Inc's (NASDAQ: AVRO) AVR-RD-04, its gene therapy to treat cystinosis. AVR-RD-04 consists of the patient's hematopoietic stem cell
Avrobio: An Update After Stock Price Drop After bluebird Trial Halt
07:11pm, Wednesday, 17'th Feb 2021
AVRO dropped after bluebird's lentiglobin trials were halted because of AML/MDS concerns. Both therapies use Lentiviral vectors, hence the concern.
